Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why Universal Display Stock Dropped Today (Fool) +++ UNIVERSAL DISPLAY Aktie +3,45%

IPSEN Aktie

 >IPSEN Aktienkurs 
124.1 EUR    +0.7%    (Tradegate)
Ask: 125.3 EUR / 8 Stück
Bid: 124.7 EUR / 9 Stück
Tagesumsatz: 61 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IPSEN Aktie über LYNX handeln
>IPSEN Performance
1 Woche: +2,5%
1 Monat: +6,3%
3 Monate: +16,6%
6 Monate: +21,9%
1 Jahr: +12,3%
laufendes Jahr: +12,4%
>IPSEN Aktie
Name:  IPSEN S.A. PORT. EO 1
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0010259150 / A0ESMG
Symbol/ Ticker:  I7G (Frankfurt)
Kürzel:  FRA:I7G, ETR:I7G, I7G:GR
Index:  -
Webseite:  https://www.ipsen.com/
Profil:  Ipsen S.A. is a global biopharmaceutical company s..
>Volltext..
Marktkapitalisierung:  10164.51 Mio. EUR
Unternehmenswert:  9683.5 Mio. EUR
Umsatz:  3626.63 Mio. EUR
EBITDA:  1623.33 Mio. EUR
Nettogewinn:  456.14 Mio. EUR
Gewinn je Aktie:  5.51 EUR
Schulden:  979.5 Mio. EUR
Liquide Mittel:  1471.59 Mio. EUR
Operativer Cashflow:  990.9 Mio. EUR
Bargeldquote:  1.02
Umsatzwachstum:  9.57%
Gewinnwachstum:  -34.25%
Dividende je Aktie:  1.4 EUR
Dividendenrendite:  1.14%
Dividendenschätzung:  1.13%
Div. Historie:  04.06.25 - 1.4€
30.05.24 - 1.2€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  IPSEN
Letzte Datenerhebung:  08.11.25
>IPSEN Kennzahlen
Aktien/ Unternehmen:
Aktien: 82.71 Mio. St.
Frei handelbar: 41.78%
Leerverk. Aktien: -
Rückkaufquote: 0.34%
Mitarbeiter: 5358
Umsatz/Mitarb.: 0.57 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 4.29%
Bewertung:
KGV: 23.36
KGV lG: 11.09
KUV: 2.75
KBV: 2.45
PEG-Ratio: -
EV/EBITDA: 5.97
Rentabilität:
Bruttomarge: 82.39%
Gewinnmarge: 12.58%
Operative Marge: 33.67%
Managementeffizenz:
Gesamtkaprendite: 6.7%
Eigenkaprendite: 10.82%
>IPSEN Peer Group

Es sind 69 Aktien bekannt.
 
07.11.25 - 18:03
 Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
07.11.25 - 14:45
 Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®′s long-term efficacy, safety and mechanistic insights in fatigue (GlobeNewswire EN)
 
Paris, France – 7 November, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the ELATIVE trial1, 2 will be presented in two late-breaking sessions, at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD).  ...
22.10.25 - 14:24
 Ipsen übertrifft Prognosen und hebt Jahresziel an – Aktie legt deutlich zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.10.25 - 11:31
 Ipsen Q3 Total Sales Rise, Lifts FY25 Outlook; To Buy ImCheck; Stock Up (AFX)
 
PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a specialty-care biopharmaceutical company, Wednesday reported higher total sales for the third quarter compared to last year, mainly driven by strong......
22.10.25 - 11:01
 Ipsen stock jumps 6% after upbeat Q3 and higher outlook on Somatuline boost (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.10.25 - 10:03
 EQT Life Sciences′ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion (PR Newswire)
 
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck's shareholders will be eligible to receive a payment of EUR 350 million and downstream payments, for a total potential consideration of up to EUR 1 billion. ImCheck Therapeutics is a private......
22.10.25 - 09:48
 Ipsen To Buy ImCheck Therapeutics In Up To $1 Bln Deal; Stock Up (AFX)
 
PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a biopharmaceutical company, Wednesday announced that it entered into a definite agreement to purchase ImCheck Therapeutics for a total consideration ......
22.10.25 - 09:15
 Ipsen S.A. reports Q3 results; upgrades FY outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.10.25 - 09:03
 Corporate News: Andera Partners (EQS)
 
Ipsen to acquire ImCheck Therapeutics, in Andera Partners' portfolio, expanding its leadership in oncology, strengthening its pipeline...
22.10.25 - 07:09
 Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance (GlobeNewswire EN)
 
PARIS, FRANCE, 22 October 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025....
22.10.25 - 07:03
 Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline (GlobeNewswire EN)
 
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. The anticipated acquisition is focused on the lead Phase I/II program ICT01 in first line acute myeloid leukemia (AML)3 patients who are ineligible for intensive chemotherapy. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, and received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025....
07.10.25 - 18:03
 Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
22.09.25 - 08:06
 Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy (AFX)
 
PARIS (dpa-AFX) - Ipsen (IPSEY) announced first aesthetic data for glabellar lines from Stage 1 of its multi-stage, ongoing Phase II LANTIC trial evaluating the internally developed IPN10200. Pati......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer zu den Traumdeutern geht, verschleudert sein bestes Gut und verdient die Sklaverei, in die er so unweigerlich gerät. - Dr. Elias Canetti
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!